1. Home
  2. SII vs NVAX Comparison

SII vs NVAX Comparison

Compare SII & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SII
  • NVAX
  • Stock Information
  • Founded
  • SII 2008
  • NVAX 1987
  • Country
  • SII Canada
  • NVAX United States
  • Employees
  • SII N/A
  • NVAX N/A
  • Industry
  • SII Finance: Consumer Services
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SII Finance
  • NVAX Health Care
  • Exchange
  • SII Nasdaq
  • NVAX Nasdaq
  • Market Cap
  • SII 1.1B
  • NVAX 1.3B
  • IPO Year
  • SII N/A
  • NVAX 1995
  • Fundamental
  • Price
  • SII $58.02
  • NVAX $7.34
  • Analyst Decision
  • SII
  • NVAX Buy
  • Analyst Count
  • SII 0
  • NVAX 5
  • Target Price
  • SII N/A
  • NVAX $19.00
  • AVG Volume (30 Days)
  • SII 199.7K
  • NVAX 14.2M
  • Earning Date
  • SII 05-07-2025
  • NVAX 05-08-2025
  • Dividend Yield
  • SII 2.07%
  • NVAX N/A
  • EPS Growth
  • SII 10.23
  • NVAX N/A
  • EPS
  • SII 1.93
  • NVAX 2.97
  • Revenue
  • SII $180,474,000.00
  • NVAX $1,254,962,000.00
  • Revenue This Year
  • SII $0.57
  • NVAX $40.01
  • Revenue Next Year
  • SII $8.89
  • NVAX N/A
  • P/E Ratio
  • SII $30.03
  • NVAX $2.47
  • Revenue Growth
  • SII 17.97
  • NVAX 25.92
  • 52 Week Low
  • SII $38.41
  • NVAX $5.01
  • 52 Week High
  • SII $59.14
  • NVAX $23.86
  • Technical
  • Relative Strength Index (RSI)
  • SII 69.82
  • NVAX 55.86
  • Support Level
  • SII $56.01
  • NVAX $6.84
  • Resistance Level
  • SII $59.14
  • NVAX $7.62
  • Average True Range (ATR)
  • SII 1.21
  • NVAX 0.55
  • MACD
  • SII -0.02
  • NVAX 0.07
  • Stochastic Oscillator
  • SII 83.26
  • NVAX 50.52

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: